Fuji Pharma Co., Ltd. (TYO:4554)
Japan
· Delayed Price · Currency is JPY 2,304.00
+52.00 (2.31%)
Mar 10, 2026, 1:43 PM JST
Fuji Pharma Cash Flow Statement
Financials in millions JPY. Fiscal year is October - September.
Millions JPY. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | 2020 - 2016 |
| Net Income | - | 4,000 | 8,276 | 4,399 | 3,723 | 3,371 | Upgrade
|
| Depreciation & Amortization | - | 3,965 | 3,680 | 3,023 | 2,745 | 2,106 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | 394 | - | 4 | 1 | 33 | Upgrade
|
| Loss (Gain) From Sale of Investments | - | - | -3,118 | - | - | -153 | Upgrade
|
| Other Operating Activities | - | -2,193 | -1,027 | -941 | -1,504 | -915 | Upgrade
|
| Change in Accounts Receivable | - | 525 | -1,997 | -3,705 | -549 | -174 | Upgrade
|
| Change in Inventory | - | -3,078 | 1,552 | -3,395 | -3,618 | -1,340 | Upgrade
|
| Change in Accounts Payable | - | 356 | -1,640 | -652 | 447 | 2,038 | Upgrade
|
| Change in Other Net Operating Assets | - | 1,832 | -1,575 | 3,184 | -1,903 | 1,027 | Upgrade
|
| Operating Cash Flow | - | 5,801 | 4,151 | 1,917 | -658 | 5,993 | Upgrade
|
| Operating Cash Flow Growth | - | 39.75% | 116.54% | - | - | 3.86% | Upgrade
|
| Capital Expenditures | - | -1,981 | -2,778 | -3,327 | -5,097 | -3,789 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 2 | 2 | 10 | 1,383 | 1,673 | Upgrade
|
| Sale (Purchase) of Intangibles | - | -1,873 | -1,594 | -570 | -7,326 | -107 | Upgrade
|
| Investment in Securities | - | - | 5,356 | - | - | 189 | Upgrade
|
| Other Investing Activities | - | -367 | -2,644 | -1,353 | -231 | -311 | Upgrade
|
| Investing Cash Flow | - | -4,219 | -1,658 | -5,240 | -11,271 | -2,345 | Upgrade
|
| Short-Term Debt Issued | - | - | 4,000 | 3,000 | 1,300 | 6,000 | Upgrade
|
| Long-Term Debt Issued | - | 9,987 | - | 2,985 | 7,300 | 1,000 | Upgrade
|
| Total Debt Issued | - | 9,987 | 4,000 | 5,985 | 8,600 | 7,000 | Upgrade
|
| Long-Term Debt Repaid | - | -7,749 | -5,210 | -2,740 | -2,140 | -1,756 | Upgrade
|
| Total Debt Repaid | - | -7,749 | -5,210 | -2,740 | -2,140 | -1,756 | Upgrade
|
| Net Debt Issued (Repaid) | - | 2,238 | -1,210 | 3,245 | 6,460 | 5,244 | Upgrade
|
| Issuance of Common Stock | - | 210 | 55 | - | - | 11 | Upgrade
|
| Repurchase of Common Stock | - | - | - | - | - | -9,405 | Upgrade
|
| Common Dividends Paid | - | -1,036 | -972 | -899 | -729 | -807 | Upgrade
|
| Other Financing Activities | - | -458 | 1,692 | -431 | -637 | -478 | Upgrade
|
| Financing Cash Flow | - | 954 | -435 | 1,915 | 5,094 | -5,435 | Upgrade
|
| Foreign Exchange Rate Adjustments | - | 123 | 202 | 185 | 183 | -55 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | - | 1 | - | 2 | -1 | - | Upgrade
|
| Net Cash Flow | - | 2,660 | 2,260 | -1,221 | -6,653 | -1,842 | Upgrade
|
| Free Cash Flow | - | 3,820 | 1,373 | -1,410 | -5,755 | 2,204 | Upgrade
|
| Free Cash Flow Growth | - | 178.22% | - | - | - | -36.08% | Upgrade
|
| Free Cash Flow Margin | - | 7.39% | 2.98% | -3.45% | -16.25% | 6.48% | Upgrade
|
| Free Cash Flow Per Share | - | 156.54 | 56.48 | -58.02 | -236.90 | 82.03 | Upgrade
|
| Cash Interest Paid | - | 327 | 194 | 104 | 82 | 59 | Upgrade
|
| Cash Income Tax Paid | - | 2,197 | 1,026 | 946 | 1,498 | 911 | Upgrade
|
| Levered Free Cash Flow | - | 535.5 | 599.13 | -4,258 | -11,724 | 1,392 | Upgrade
|
| Unlevered Free Cash Flow | - | 741.75 | 721.63 | -4,182 | -11,676 | 1,425 | Upgrade
|
| Change in Working Capital | - | -365 | -3,660 | -4,568 | -5,623 | 1,551 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.